Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Randomized, Double-blind, Positive-controlled Dose-exploration Study to Evaluate the Safety and Immunogenicity of a Virus-like Particle (VLP) Based Vaccine Against Poliomyelitis (VLP-Polio) in Infants From 6 Weeks of Age and Toddlers 12-18 Months of Age

NCT06577298 is registered in ClinicalTrials.gov with CanSino Biologics Inc. as lead sponsor.

NCT NCT06577298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06577298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Randomized, Double-blind, Positive-controlled Dose-exploration Study to Evaluate the Safety and Immunogenicity of a Virus-like Particle (VLP) Based Vaccine Against Poliomyelitis (VLP-Polio) in Infants From 6 Weeks of Age and Toddlers 12-18 Months of Age
Lead sponsor
CanSino Biologics Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 19, 2024
Completion date
December 31, 2026
Enrollment
480 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

poliomyelitis